 Shares of DarioHealth NASDAQ:DRIO remained unaffected at 7.95 after the company reported Q1 results.Quarterly Results Earnings per share fell 946.67 year over year to 1.57, which missed the estimate of 0.75.Revenue of 1,667,000 less by 25.65 year over year, which missed the estimate of 1,750,000.Guidance DarioHealth hasnt issued any earnings guidance for the time being.Revenue guidance hasnt been issued by the company for now.How To Listen To The Conference Call Date: May 12, 2020View more earnings on DRIOTime: 08:04 PM ETWebcast URL: Companys 52-week high was at 11.2552-week low: 0.20Price action over last quarter: Up 109.21Company Overview DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The companys product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.See more from Benzinga Stocks That Hit 52-Week Lows On Monday A Look Into AMC Entertainments Price Over Earnings Stocks That Hit 52-Week Highs On MondayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 